Should We Pay for Organ Donation? The Ethics of a Legal Kidney Market

Every day, patients with kidney, liver, heart, and lung failure wait for a call that may never come. Modern transplant medicine can save or transform many of these lives, but the supply of transplantable organs has never matched the need.

In the United States, more than 100,000 people are listed for an organ transplant through the national system overseen by the Organ Procurement and Transplantation Network. Most are waiting for kidneys. According to federal transplant data, roughly 17 people die each day while waiting. Globally, the gap is even wider. The World Health Organization has long warned that transplant activity meets only a fraction of worldwide need, especially in countries with limited donation systems, dialysis access, or transplant infrastructure.

That shortage has led to one of the hardest questions in medicine and bioethics: should society keep relying only on altruistic donation, or should living donors be allowed to receive payment for organs such as a kidney?

The organ shortage is not abstract for patients waiting for a transplant.

Why the organ shortage creates pressure for change

Kidney disease shows the issue clearly. A healthy person can usually live with one kidney, which makes living kidney donation medically possible. For many patients with kidney failure, a transplant offers longer survival and better quality of life than long-term dialysis. It can also cost health systems less over time, since dialysis is expensive and ongoing.

Yet living donation asks a great deal from the donor. A donor must undergo medical testing, surgery, recovery, lost work time, and a small but real risk of complications. Many donors give to a relative, friend, or stranger without payment. That gift is often described as one of the clearest examples of medical altruism.

The problem is that altruism does not produce enough organs. Deceased donation is limited by death circumstances, family consent, medical suitability, and hospital systems. Living donation is limited by health, compatibility, fear, financial strain, and the simple fact that many people do not feel able to donate an organ without a compelling personal reason.

The proposal for a legal kidney market starts with this reality. Supporters argue that if society compensates people for risky work, pharmaceutical trial participation, egg donation, sperm donation, and plasma donation, it should at least consider fair compensation for kidney donation under strict medical oversight.

This is where the debate begins.

What a compensated donation system might look like

A legal market for organ donation does not have to mean a person selling a kidney in a direct bargain with the highest bidder. Many serious proposals describe a regulated system, not an open marketplace.

A regulated model might include:

• Government-set compensation rather than private bidding

• Medical and psychological screening for all donors

• Independent donor advocates

• A waiting period before consent becomes final

• Long-term health insurance and follow-up care for donors

• Allocation through the existing transplant list, not by wealth

• A ban on brokers, transplant tourism, and private side deals

  
  

Under this approach, a donor might receive a fixed payment, tax credit, education benefit, debt relief, housing support, lifetime health coverage, or a combination of benefits. The organ would still go to a patient based on medical need and allocation rules, not to the person who can pay the most.

Supporters see this as a way to reduce harm in a system where need already exists. Critics worry that changing the language from “donation” to “sale” would alter the moral foundation of transplantation.

The case for paying living kidney donors

Economists often start with supply and demand. When a valuable good is scarce and the law bans payment, shortages are likely. From this view, the ban on organ sales may protect an ethical ideal while leaving patients to suffer preventable deaths.

A compensated system could bring several possible benefits.

More organs could become available. If payment encouraged even a small share of healthy adults to donate, waiting lists could fall. Kidney patients might spend less time on dialysis. Families might avoid years of uncertainty.

Patients could receive transplants earlier. Time matters. The longer a patient remains on dialysis, the more health can decline. Earlier transplantation often means better outcomes, though individual results vary.

Illegal trafficking could become less attractive. The WHO, the Declaration of Istanbul Custodian Group, and transplant ethics organizations have condemned organ trafficking and transplant tourism. These practices can exploit poor donors, bypass medical safeguards, and leave donors without care. Supporters of legalization argue that a transparent system could undercut black markets by offering safer, regulated opportunities.

Donors could be treated more fairly. Some donors already bear costs. They may lose wages, pay for travel, arrange childcare, or face insurance worries. Many countries allow reimbursement for direct expenses, but reimbursement is not the same as compensation. Supporters say it is unfair to praise donors as heroes while allowing them to absorb financial harm.

Transplant recipients often see the issue through a personal lens. For someone waiting years for a kidney, compensation can look less like commodification and more like a practical way to save lives. Some recipients also argue that if surgeons, hospitals, drug companies, and insurers are paid within the transplant system, the donor should not be the only person barred from financial benefit.

Supporters of compensation often focus on patients who may never receive an organ in time.

The ethical case against organ sales

Opponents of payment do not deny the shortage. Their concern is that a market could solve one ethical problem by creating others.

Exploitation and poverty

The strongest objection is exploitation. If payment is legal, people with low incomes may become the main source of organs for people with greater resources, even if allocation rules try to prevent that. A choice made under financial desperation may be formally voluntary but morally troubling.

A person who sells a kidney to pay rent, escape debt, or cover medical bills may not be choosing from a fair set of options. Ethicists often ask whether consent can be meaningful when the alternative is hunger, eviction, or family crisis.

This concern is not theoretical. Studies of illegal and poorly regulated organ markets have found that many sellers remain poor afterward, experience health problems, or feel regret and social stigma. The exact findings vary by country and study design, but the pattern has shaped international opposition to organ commercialization.

Coercion and family pressure

Payment can also create pressure within families. A relative might be pushed to donate because the household needs money. A young adult might feel responsible for solving a parent’s debt. A spouse might face pressure that is hard for doctors to detect.

Transplant teams already screen living donors for coercion. Payment would make that job harder. The larger the reward, the stronger the pressure could become.

Inequality in who gives and who receives

Even with fair allocation, a compensated system may deepen social inequality. Wealthier patients would likely have better access to transplant centers, lawyers, second opinions, and post-transplant care. Poorer donors may face higher long-term risks if they have less access to follow-up care, healthy food, safe housing, or primary care.

Physicians worry about this because donation does not end at surgery. A living kidney donor needs lifelong attention to blood pressure, kidney function, and general health. A payment at the time of donation cannot replace decades of medical care.

Informed consent and unknown long-term risk

Living kidney donation is generally safe for carefully selected donors, according to transplant organizations such as the American Society of Transplantation and the National Kidney Foundation. Still, “generally safe” does not mean risk-free.

Donors face surgical risks, recovery time, and possible long-term changes in kidney function. Some research suggests certain groups may face higher lifetime risk of kidney disease after donation than others, based on age, family history, race, hypertension risk, and other factors. A person focused on immediate financial need may discount risks that unfold years later.

Commodification of the body

Some ethicists argue that selling organs changes the meaning of the human body. In this view, body parts should not be treated like property. Turning organs into commodities may weaken human dignity and erode the gift-based culture that supports donation.

Others reject that argument. They note that people already make choices involving their bodies in paid labor, military service, medical research, and reproductive medicine. The key question, they say, is not whether money is involved, but whether people are protected, informed, and treated with respect.

The hardest ethical questions center on consent, pressure, and financial need.

What current laws say in many countries

Most countries prohibit buying and selling human organs. In the United States, the National Organ Transplant Act of 1984 bans “valuable consideration” for human organs, while allowing reimbursement for some donation-related expenses. Similar bans exist across much of Europe, Canada, Australia, and many other regions.

International guidance takes the same position. The WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation oppose organ sales and call for donation to be voluntary and unpaid. The Declaration of Istanbul also condemns organ trafficking and transplant tourism, with a focus on protecting vulnerable people.

These policies reflect a broad medical consensus: organs should be donated as gifts, not sold as goods.

At the same time, many systems now recognize that donors should not suffer financial loss. Reimbursement for travel, lodging, lost wages, and dependent care has gained support because it removes barriers without creating a profit motive. Some ethicists see expanded reimbursement as a middle path between pure altruism and a market.

Iran’s compensated kidney donation system is the key real-world example

Iran is often cited because it has a regulated system for compensated living kidney donation. The model is complex and has changed over time, so it should not be reduced to a simple success story or cautionary tale.

In broad terms, Iran permits kidney donors to receive compensation through a regulated process. Reports describe government involvement, nonprofit patient associations, fixed payments or benefits in some cases, and separate arrangements between donors and recipients in others. Deceased donation also exists, but living compensated donation has played a major role.

Supporters of the Iranian model point to a major reported success: Iran is often described as having avoided the long kidney waiting lists seen in many other countries. Some scholars and physicians have argued that regulated compensation helped increase supply and gave donors at least some oversight compared with illegal markets.

Critics point to serious concerns. Research and commentary have reported that many donors come from lower-income groups, raising questions about exploitation. Some donors have described dissatisfaction, ongoing poverty, stigma, or limited long-term medical support. Critics also argue that the system has not fully removed private bargaining or inequality.

The lesson from Iran is not simple. It shows that compensation can increase kidney availability under some conditions. It also shows how hard it is to protect donors when poverty drives decisions.

How different experts view the tradeoff

Physicians often focus on the patient in front of them and the donor they must not harm. A transplant surgeon may see preventable deaths on the waiting list, then meet a potential donor whose financial distress raises alarms. The medical ethic of “do no harm” applies to both people.

Ethicists tend to ask about dignity, justice, and consent. They challenge whether a market can ever be fair when the likely sellers are poor and the likely recipients have more social power. Some accept compensation only if it is noncash, modest, and paired with lifelong donor care.

Economists often ask whether the current ban causes more harm than it prevents. If thousands die waiting and black markets continue, they argue, a regulated system might be more ethical than prohibition. Some propose government monopsony models, where the state is the only legal purchaser and organs are allocated by medical need.

Transplant recipients may favor any policy that gives them a fair chance to live. Yet many also worry about receiving an organ from someone who felt trapped by poverty. Gratitude can sit beside discomfort.

Living donors are not one group. Some unpaid donors describe donation as a meaningful gift they would not want commercialized. Others say donors deserve more than praise, especially when they face lost wages or long recovery. Some people who sold kidneys in unregulated settings have reported regret, while others say payment helped them in a difficult moment. Their voices should be central because they bear the physical risk.

Recipients and donors often experience the ethics of transplantation in deeply personal ways.

Possible middle paths short of organ sales

The debate is often framed as a choice between unpaid donation and a full market. Real policy choices are broader.

Countries could expand:

• Reimbursement for all donor expenses

• Paid medical leave for living donors

• Guaranteed lifelong follow-up care

• Priority on a transplant list if a donor later needs an organ

• Public education about deceased donation

• Opt-out deceased donation systems, when paired with public trust and strong safeguards

• Paired kidney exchange programs

• Better prevention and treatment of diabetes, hypertension, and kidney disease

  
  

These steps may not erase the shortage, but they can reduce it without crossing the line into organ sales.

A more debated middle path is regulated compensation without private buying. This could treat donors as public contributors rather than sellers in a market. Critics still worry that money would target the poor. Supporters say the ethical details matter, including the amount, form of payment, screening, and long-term care.

The central question is what society owes to both patients and donors

The ethics of paid organ donation cannot be answered by supply numbers alone. More kidneys would save lives. Poorly designed payment could also exploit the very people medicine should protect.

A fair debate has to hold two truths at once. Patients are dying because organs are scarce. People in financial distress should not become a biological resource for those with better options.

Reputable medical and ethical sources, including the WHO, the Declaration of Istanbul, the National Kidney Foundation, the American Medical Association’s ethics guidance, and national transplant authorities, generally support voluntary donation and oppose organ sales. Yet ongoing shortages keep the question alive among economists, bioethicists, physicians, patients, and donors.

Information in this article is educational and not medical or legal advice. Transplant policy varies by country, and anyone considering living donation should speak with qualified transplant professionals and independent donor advocates.

The final question is not only whether compensation would increase organ supply. It is whether society can design a system that saves recipients without exploiting donors. Should organs remain gifts, protected from market forces? Or could carefully regulated compensation ever be ethical if it reduces suffering, prevents illegal trafficking, and gives donors real protection?

The answer depends on what we believe a human organ is: a gift that should never be priced, or a lifesaving resource that might be shared ethically with safeguards strong enough to protect the people who give.